RIPK1 and neoplasm: Mice treated with either endothelial cell-specific RIPK3 deletion or receptor-interacting serine/threonine-protein kinase 1 (RIPK1)-inhibitor necrostatin-1 showed a reduction in tumor-cell-induced endothelial necroptosis, tumor cell extravasation, and metastasis.